Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/35649
Tipo de documento
ArtigoDireito Autoral
Acesso aberto
Data de embargo
2020-09-18
Coleções
- INI - Artigos de Periódicos [3391]
Metadata
Mostrar registro completo
MOVING RECEPTOR REDIRECTED ADOPTIVE CELL THERAPY TOWARD FINE TUNING OF ANTITUMOR RESPONSES
Cancer
Chimeric antigen receptor
Gene therapy
Immunotherapy
Off-target
Tumor antigen
Autor(es)
Afiliação
Instituto Nacional de Câncer. Coordenação de Pesquisa. Programa de Carcinogênese Molecular. Rio de Janeiro, RJ, Brasil / Fundação Instituto Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Instituto Nacional de Câncer. Coordenação de Pesquisa. Programa de Carcinogênese Molecular. Rio de Janeiro, RJ, Brasil.
Instituto Nacional de Câncer. Coordenação de Pesquisa. Programa de Carcinogênese Molecular. Rio de Janeiro, RJ, Brasil.
Resumo em Inglês
Adoptive cell transfer (ACT) is emerging as a powerful modality of cancer treatment. While ACT has proved able to induce massive clinical responses, genetic modification of T lymphocytes further improved clinical responses obtained. One of the major current limitations of ACT is the inability to discern healthy from malignant cells, leading to on target/off tumor responses that can limit its application. We here discuss some of the approaches currently under development and potential solutions to circumvent these limitations and extend this potentially curative therapy to different tumors by targeting a variety of antigens.
Palavras-chave em inglês
Adoptive cell therapyCancer
Chimeric antigen receptor
Gene therapy
Immunotherapy
Off-target
Tumor antigen
Compartilhar